Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine plus LISA versus LISA alone in preterm infants with respiratory distress syndrome
IRCT20260525069524N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory distress syndrome (RDS) comparing Caffeine + LISA with Placebo + LISA (2 arms). Primary endpoint: CPAP failure. Started May 2024; status: completed.
02
Drugs
caffeine
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20260525069524N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260525069524N1.